Trial Profile
Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; TRC 102 (Primary)
- Indications Glioblastoma; Lung cancer
- Focus Therapeutic Use
- 14 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 28 Feb 2019 Primary endpoint has not been met. (Objective response (Arm I)) according to a TRACON Pharmaceuticals media release
- 07 Nov 2018 According to a TRACON Pharmaceuticals media release, safety and efficacy data will be presented at the Society for Neuro-Oncology annual meeting in November 2018.